$EUDA
EUDA Health Holdings Ltd Stock $euda

$euda Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000149315222033257 Filed on November 22, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q4
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue	$1.617M
YoY Change
Gross Profit	$817.6K
YoY Change
Gross Profit Margin
Selling, General & Admin	$9.346M
YoY Change
% of Gross Profit	1143.09%
Research & Development	$2.150K
YoY Change
% of Gross Profit	0.26%
Depreciation & Amortization	$147.2K
YoY Change
% of Gross Profit	18.0%
Operating Expenses	$300.0K	$1.233M
YoY Change		14612.29%
Operating Profit	-$298.3K		-$45.59K
YoY Change	554.42%
Interest Expense	$500.0K	$213.5K
YoY Change
% of Operating Profit
Other Income/Expense, Net	$499.3K
YoY Change
Pretax Income	$200.0K	-$1.019M
YoY Change		12064.32%
Income Tax	-$57.10K
% Of Pretax Income	-28.55%
Net Earnings	$201.0K	-$1.019M	-$45.59K
YoY Change	-540.94%	12064.32%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	$0.02	-$91.80K
COMMON SHARES
Basic Shares Outstanding	20.19M shares	11.07M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$270.0K	$193.6K
YoY Change
Cash & Equivalents	$265.9K	$193.5K
Short-Term Investments
Other Short-Term Assets	$87.00M	$86.58M
YoY Change
Inventory
Prepaid Expenses	$30.61K	$109.1K
Receivables	$1.852M		$1.802M
Other Receivables	$7.467K		$1.991M
Total Short-Term Assets	$87.27M	$86.78M	$4.353M
YoY Change	1904.95%	20131.19%
LONG-TERM ASSETS
Property, Plant & Equipment	$31.63K		$56.93K
YoY Change	-44.44%
Goodwill			$992.7K
YoY Change			-1.97%
Intangibles	$0.00		$290.0K
YoY Change	-100.0%
Long-Term Investments
YoY Change
Other Assets	$478.1K
YoY Change
Total Long-Term Assets	$0.00	$0.00	$3.646M
YoY Change	-100.0%
TOTAL ASSETS
Total Short-Term Assets	$87.27M	$86.78M	$4.353M
Total Long-Term Assets	$0.00	$0.00	$3.646M
Total Assets	$87.27M	$86.78M	$7.999M
YoY Change	990.99%	20131.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.635M		$359.7K
YoY Change	354.66%
Accrued Expenses	$671.7K	$824.4K	$129.0K
YoY Change	420.61%	22548.63%
Deferred Revenue
YoY Change
Short-Term Debt	$1.000M	$800.0K
YoY Change
Long-Term Debt Due	$7.190K
YoY Change
Total Short-Term Liabilities	$29.12M	$4.730M	$7.316M
YoY Change	298.04%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00
YoY Change
Total Long-Term Liabilities	$15.02K	$0.00	$82.95K
YoY Change	-81.9%
TOTAL LIABILITIES
Total Short-Term Liabilities	$29.12M	$4.730M	$7.316M
Total Long-Term Liabilities	$15.02K	$0.00	$82.95K
Total Liabilities	$5.022M	$4.730M	$7.399M
YoY Change	-32.12%	1083.11%
SHAREHOLDERS EQUITY
Retained Earnings	-$4.022M	-$3.724M	$180.3K
YoY Change	-2330.25%	44349.68%
Common Stock	$0.00	$0.00	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$4.022M	-$3.724M	-$16.46K
YoY Change
Total Liabilities & Shareholders Equity	$87.27M	$86.78M	$7.999M
YoY Change	990.99%	20131.19%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q4
OPERATING ACTIVITIES
Net Income	$201.0K	-$1.019M	-$45.59K
YoY Change	-540.94%	12064.32%
Depreciation, Depletion And Amortization	$147.2K
YoY Change
Cash From Operating Activities	-$123.8K	-$353.3K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures	$18.14K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$250.1K	$0.00
YoY Change
Cash From Investing Activities	-$268.2K	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$196.1K	0.000
YoY Change
NET CHANGE
Cash From Operating Activities	-$123.8K	-353.3K
Cash From Investing Activities	-268.2K	0.000
Cash From Financing Activities	$196.1K	0.000
Net Change In Cash	$72.31K	-353.3K
YoY Change
FREE CASH FLOW
Cash From Operating Activities	-$123.8K	-$353.3K
Capital Expenditures	$18.14K
Free Cash Flow	-$141.9K
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q4	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q4	dei	Entity File Number EntityFileNumber	001-40678
CY2022Q4	dei	Entity Registrant Name EntityRegistrantName	EUDA HEALTH HOLDINGS LIMITED
CY2022Q4	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	D8
CY2022Q4	dei	Entity Address Address Line1 EntityAddressAddressLine1	1 Pemimpin Drive #12-07
CY2022Q4	dei	Entity Address City Or Town EntityAddressCityOrTown	One Pemimpin
CY2022Q4	dei	Entity Address Country EntityAddressCountry	SG
CY2022Q4	dei	Entity Central Index Key EntityCentralIndexKey	0001847846
CY2022Q4	dei	Amendment Flag AmendmentFlag	false
CY2022Q4	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--07-31
CY2022Q4	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue		usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue		usd
CY2022Q4	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2022	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital		usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital		usd
CY2021Q4	EUDA	Dividends On Marketable Securities Held In Trust DividendsOnMarketableSecuritiesHeldInTrust		usd
CY2021Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense		usd
CY2021Q4	EUDA	Basic And Diluted Weighted Average Redeemable Ordinary Shares Outstanding Basic And Diluted BasicAndDilutedWeightedAverageRedeemableOrdinarySharesOutstandingBasicAndDiluted		shares
CY2021Q4	EUDA	Basic And Diluted Net Income Per Redeemable Ordinary Share BasicAndDilutedNetIncomePerRedeemableOrdinaryShare
CY2022Q4	EUDA	Formation And Operating Costs Paid By Related Party FormationAndOperatingCostsPaidByRelatedParty		usd
CY2021Q4	EUDA	Dividends Earned On Cash And Marketable Securities Held In Trust Account DividendsEarnedOnCashAndMarketableSecuritiesHeldInTrustAccount		usd
CY2021Q4	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities		usd
CY2021Q4	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties		usd
CY2021Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities		usd
CY2021Q4	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2021Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect		usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations		usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations		usd
CY2022Q4	EUDA	Deferred Offering Costs Paid By Related Party DeferredOfferingCostsPaidByRelatedParty		usd
CY2022Q4	EUDA	Deferred Offering Costs Included In Accrued Offering Costs And Expenses DeferredOfferingCostsIncludedInAccruedOfferingCostsAndExpenses		usd
CY2021Q4	EUDA	Subsequent Measurement Of Ordinary Shares Subject To Possible Redemption SubsequentMeasurementOfOrdinarySharesSubjectToPossibleRedemption		usd
CY2021Q4	EUDA	Conversion Of Due To Related Party Into Promissory Note ConversionOfDueToRelatedPartyIntoPromissoryNote		usd
CY2021Q4	EUDA	Temporary Equity Accretion To Redemption Value After Net Income Loss TemporaryEquityAccretionToRedemptionValueAfterNetIncomeLoss		usd
CY2022Q4	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2022Q4	dei	Document Type DocumentType	10-Q
CY2022Q4	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q4	dei	Document Period End Date DocumentPeriodEndDate	2022-10-31
CY2022Q4	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	576151
CY2022Q4	dei	City Area Code CityAreaCode	65
CY2022Q4	dei	Local Phone Number LocalPhoneNumber	6268 6821
CY2022Q4	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
CY2022Q4	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q4	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q4	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q4	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022Q4	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022Q4	dei	Entity Shell Company EntityShellCompany	true
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	20191770	shares
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	265852	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	193546	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	30606	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	109143	usd
CY2022Q4	us-gaap	Assets Held In Trust Current AssetsHeldInTrustCurrent	86972255	usd
CY2022Q3	us-gaap	Assets Held In Trust Current AssetsHeldInTrustCurrent	86472912	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	87268713	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	86775601	usd
CY2022Q4	us-gaap	Assets Assets	87268713	usd
CY2022Q3	us-gaap	Assets Assets	86775601	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	890404	usd
CY2022Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	824410	usd
CY2022Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	113000	usd
CY2022Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	86894	usd
CY2022Q4	EUDA	Promissory Note Related Party PromissoryNoteRelatedParty	1000000	usd
CY2022Q3	EUDA	Promissory Note Related Party PromissoryNoteRelatedParty	800000	usd
CY2022Q4	us-gaap	Deferred Leasing Commissions DeferredLeasingCommissions	3018750	usd
CY2022Q3	us-gaap	Deferred Leasing Commissions DeferredLeasingCommissions	3018750	usd
CY2022Q4	us-gaap	Liabilities Liabilities	5022154	usd
CY2022Q3	us-gaap	Liabilities Liabilities	4730054	usd
CY2022Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	8225000	shares
CY2022Q3	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	8225000	shares
CY2022Q4	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	10.08
CY2022Q3	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	10.03
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	400000	shares
CY2022Q3	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	400000	shares
CY2022Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	8.32
CY2022Q3	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	8.27
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	86268440	usd
CY2022Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	85769097	usd
CY2022Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2022Q3	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2448500	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2448500	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2448500	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2448500	shares
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4021881	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3723550	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-4021881	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-3723550	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	87268713	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	86775601	usd
CY2022Q4	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	298331	usd
CY2021Q4	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	45587	usd
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-298331	usd
CY2021Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-45587	usd
CY2022Q4	EUDA	Dividends On Marketable Securities Held In Trust DividendsOnMarketableSecuritiesHeldInTrust	499343	usd
CY2022Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	499343	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	201012	usd
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-45587	usd
CY2022Q4	EUDA	Basic And Diluted Weighted Average Redeemable Ordinary Shares Outstanding Basic And Diluted BasicAndDilutedWeightedAverageRedeemableOrdinarySharesOutstandingBasicAndDiluted	8625000	shares
CY2022Q4	EUDA	Basic And Diluted Net Income Per Redeemable Ordinary Share BasicAndDilutedNetIncomePerRedeemableOrdinaryShare	0.03
CY2022Q4	EUDA	Weighted Average Shares Outstanding Of Nonredeemable Ordinary Shares WeightedAverageSharesOutstandingOfNonredeemableOrdinaryShares	2448500	shares
CY2021Q4	EUDA	Weighted Average Shares Outstanding Of Nonredeemable Ordinary Shares WeightedAverageSharesOutstandingOfNonredeemableOrdinaryShares	1875000	shares
CY2022Q4	EUDA	Basic And Diluted Net Loss Per Share Nonredeemable Ordinary Shares BasicAndDilutedNetLossPerShareNonredeemableOrdinaryShares	-0.03
CY2021Q4	EUDA	Basic And Diluted Net Loss Per Share Nonredeemable Ordinary Shares BasicAndDilutedNetLossPerShareNonredeemableOrdinaryShares	-0.02
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-3723550	usd
CY2022Q4	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	-499343	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	201012	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-4021881	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	29123	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	29123	usd
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-45587	usd
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-45587	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-16464	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-16464	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	201012	usd
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-45587	usd
CY2021Q4	EUDA	Formation And Operating Costs Paid By Related Party FormationAndOperatingCostsPaidByRelatedParty	-136	usd
CY2022Q4	EUDA	Dividends Earned On Cash And Marketable Securities Held In Trust Account DividendsEarnedOnCashAndMarketableSecuritiesHeldInTrustAccount	499343	usd
CY2022Q4	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-78537	usd
CY2021Q4	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-45451	usd
CY2022Q4	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	65994	usd
CY2022Q4	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	30000	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-123800	usd
CY2022Q4	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	196106	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	196106	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	72306	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	193546	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	265852	usd
CY2021Q4	EUDA	Deferred Offering Costs Paid By Related Party DeferredOfferingCostsPaidByRelatedParty	43222	usd
CY2021Q4	EUDA	Deferred Offering Costs Included In Accrued Offering Costs And Expenses DeferredOfferingCostsIncludedInAccruedOfferingCostsAndExpenses	63473	usd
CY2022Q4	EUDA	Subsequent Measurement Of Ordinary Shares Subject To Possible Redemption SubsequentMeasurementOfOrdinarySharesSubjectToPossibleRedemption	499343	usd
CY2022Q4	EUDA	Conversion Of Due To Related Party Into Promissory Note ConversionOfDueToRelatedPartyIntoPromissoryNote	3894	usd
CY2022Q4	us-gaap	Cash Cash	265852	usd
CY2022Q3	us-gaap	Cash Cash	193546	usd
CY2022Q4	EUDA	Working Deficit WorkingDeficit	1706946	usd
CY2022Q3	EUDA	Working Deficit WorkingDeficit	1408615	usd
CY2021Q4	us-gaap	Noninterest Expense Offering Cost NoninterestExpenseOfferingCost	5876815	usd
CY2021Q4	us-gaap	Payments For Underwriting Expense PaymentsForUnderwritingExpense	1725000	usd
CY2021Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	3018750	usd
CY2021Q4	us-gaap	Other Deferred Costs Net OtherDeferredCostsNet	649588	usd
CY2021Q4	us-gaap	Sale Of Stock Consideration Received Per Transaction SaleOfStockConsiderationReceivedPerTransaction	483477	usd
CY2021Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	25000	usd
CY2021Q4	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	87114830	usd
CY2022Q4	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_847_eus-gaap--UseOfEstimates_zQGScB3xaO1d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zzpTkB5khRwi">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of unaudited condensed financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	265852	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	193546	usd
CY2022Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	86972255	usd
CY2022Q3	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	86472912	usd
CY2022Q4	EUDA	Dividends Earned On Cash And Marketable Securities Held In Trust DividendsEarnedOnCashAndMarketableSecuritiesHeldInTrust	722255	usd
CY2022	EUDA	Dividends Earned On Cash And Marketable Securities Held In Trust DividendsEarnedOnCashAndMarketableSecuritiesHeldInTrust	222912	usd
CY2022Q4	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84E_eus-gaap--ConcentrationRiskCreditRisk_z0m5xgrFbkV2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zaDNOO9orz">Concentration of credit risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal depository insurance coverage of $<span id="xdx_906_eus-gaap--MalpracticeInsuranceCoverageFloor_c20220801__20221031_zzU9eY7jVyX4" title="Federal depository insurance coverage">250,000</span>. As of October 31, 2022 and July 31, 2022, the Company had not experienced losses on this account.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	us-gaap	Malpractice Insurance Coverage Floor MalpracticeInsuranceCoverageFloor	250000	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	201012	usd
CY2022Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	86972255	usd
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-45587	usd
CY2022Q4	EUDA	Temporary Equity Accretion To Redemption Value After Net Income Loss TemporaryEquityAccretionToRedemptionValueAfterNetIncomeLoss	499343	usd
CY2022Q4	EUDA	Net Loss Including Accretion Of Temporary Equity To Redemption Value NetLossIncludingAccretionOfTemporaryEquityToRedemptionValue	-298331	usd
CY2021Q4	EUDA	Net Loss Including Accretion Of Temporary Equity To Redemption Value NetLossIncludingAccretionOfTemporaryEquityToRedemptionValue	-45587	usd
CY2022Q4	us-gaap	Temporary Equity Aggregate Amount Of Redemption Requirement TemporaryEquityAggregateAmountOfRedemptionRequirement	3329682	usd
CY2022Q3	us-gaap	Temporary Equity Aggregate Amount Of Redemption Requirement TemporaryEquityAggregateAmountOfRedemptionRequirement	3306524	usd
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	11.50
CY2022Q4	us-gaap	Class Of Warrant Or Right Reason For Issuing To Nonemployees ClassOfWarrantOrRightReasonForIssuingToNonemployees	No fractional warrants were issued and only whole warrants trade. The Company may redeem the warrants at a price of $0.01 per warrant upon 30 days’ notice, only in the event that the last sale price of the ordinary shares is at least $16.50 per share for any 20 trading days within a 30-trading day period ending on the third day prior to the date on which notice of redemption is given, provided there is an effective registration statement and current prospectus in effect with respect to the ordinary shares underlying such warrants during the 30 day redemption period. If a registration statement is not effective within 60 days following the consummation of the Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act.
CY2022Q4	EUDA	Warrants Redemption Price WarrantsRedemptionPrice	0.01
CY2022Q4	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	86250000	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	86250000	usd
CY2022Q4	EUDA	Proceeds Allocated To Pubic Warrants And Public Rights ProceedsAllocatedToPubicWarrantsAndPublicRights	9979125	usd
CY2022	EUDA	Proceeds Allocated To Pubic Warrants And Public Rights ProceedsAllocatedToPubicWarrantsAndPublicRights	9979125	usd
CY2022Q4	EUDA	Proceeds From Issuance Of Redeemable Stock ProceedsFromIssuanceOfRedeemableStock	5196868	usd
CY2022	EUDA	Proceeds From Issuance Of Redeemable Stock ProceedsFromIssuanceOfRedeemableStock	5196868	usd
CY2022Q4	EUDA	Accretion Of Carrying Value To Redemption Value Deemed Dividend AccretionOfCarryingValueToRedemptionValueDeemedDividend	15194433	usd
CY2022	EUDA	Accretion Of Carrying Value To Redemption Value Deemed Dividend AccretionOfCarryingValueToRedemptionValueDeemedDividend	14695090	usd
CY2022Q4	EUDA	Temporary Equity Carrying Amount Subject To Possible Redemption TemporaryEquityCarryingAmountSubjectToPossibleRedemption	86268440	usd
CY2022	EUDA	Temporary Equity Carrying Amount Subject To Possible Redemption TemporaryEquityCarryingAmountSubjectToPossibleRedemption	85769097	usd
CY2022Q3	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	3894	usd
CY2022Q3	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	3894	usd
CY2022Q4	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	0	usd
CY2022Q4	us-gaap	Payment For Administrative Fees PaymentForAdministrativeFees	30000	usd
CY2021Q4	us-gaap	Payment For Administrative Fees PaymentForAdministrativeFees	0	usd
CY2021Q4	us-gaap	Underwriting Expense Ratio UnderwritingExpenseRatio	0.020	pure
CY2021Q4	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	1725000	usd
CY2021Q4	EUDA	Deferred Underwriting Expense Ratio DeferredUnderwritingExpenseRatio	0.035	pure
CY2021Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	3018750	usd
CY2021Q4	us-gaap	Other Underwriting Expense OtherUnderwritingExpense	225000	usd
CY2022Q4	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	400000	usd
CY2022Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2021Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1437500	shares
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	25000	usd
CY2022Q3	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	86472912	usd
CY2022Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	86972255	usd
CY2022Q3	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	86472912	usd
CY2022Q4	EUDA	Common Stock Redemption Value CommonStockRedemptionValue	60800000	usd

Files In Submission

Name	View Source	Status
0001493152-22-033257-index-headers.html	Edgar Link	pending
0001493152-22-033257-index.html	Edgar Link	pending
0001493152-22-033257.txt	Edgar Link	pending
0001493152-22-033257-xbrl.zip	Edgar Link	pending
euda-20221031.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
euda-20221031_pre.xml	Edgar Link	unprocessable
euda-20221031_cal.xml	Edgar Link	unprocessable
euda-20221031_def.xml	Edgar Link	unprocessable
euda-20221031_lab.xml	Edgar Link	unprocessable
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EUDA
EUDA Health Holdings Ltd Stock $euda

2022 Q4 Form 10-Q Financial Statement

#000149315222033257 Filed on November 22, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EUDA EUDA Health Holdings Ltd Stock $euda

2022 Q4 Form 10-Q Financial Statement

#000149315222033257 Filed on November 22, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EUDA
EUDA Health Holdings Ltd Stock $euda